TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst
Portfolio Pulse from
TG Therapeutics is developing a subcutaneous form of Briumvi, a multiple sclerosis drug, with initial data expected in early 2025. The company has approved a $100M share buyback but has only repurchased $2.1M in Q3'24. Further buybacks could support the stock price.
January 14, 2025 | 5:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics is developing a subcutaneous form of Briumvi, with initial data expected in early 2025. The company has approved a $100M share buyback but has only repurchased $2.1M in Q3'24. Further buybacks could support the stock price.
The development of a subcutaneous form of Briumvi could enhance TG Therapeutics' competitive position in the multiple sclerosis market, potentially boosting future revenues. The approved $100M share buyback, with only $2.1M executed in Q3'24, suggests potential for further buybacks, which could support the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100